Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

TRIAL REGISTRY: Clinicaltrials.gov #NCT01180959. BACKGROUND: Early clinical studies of bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) have a tolerable toxicity and a promising clinical outcome. We evaluated the efficacy and tolerability of this combination as a second-line ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaseb, Ahmed O, Morris, Jeffrey S, Iwasaki, Michiko, Al-Shamsi, Humaid O, Raghav, Kanwal Pratap Singh, Girard, Lauren, Cheung, Sheree, Nguyen, Van, Elsayes, Khaled M, Xiao, Lianchun, Abdel-Wahab, Reham, Shalaby, Ahmed S, Hassan, Manal, Hassabo, Hesham M, Wolff, Robert A, Yao, James C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760665/
https://www.ncbi.nlm.nih.gov/pubmed/26929648
http://dx.doi.org/10.2147/OTT.S91977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760665/
https://www.ncbi.nlm.nih.gov/pubmed/26929648
http://dx.doi.org/10.2147/OTT.S91977

Ejemplares similares